Leptospirosis Registry - LeptoScope

NCT04288674 · tracked via the Priya Life Science Germany tracker

Sponsor

University of Cologne

Phase

Observational

Started

2020-03-04

Last updated

2025-12-17

Condition(s) studied

Leptospirosis

Investigational drug(s) / intervention(s)

Retrospective data collection of demographicsRetrospective data collection of underlying diseasesRetrospective data collection of duration of hospitalization

Retrospective data collection of demographics: Retrospective data collection of demographics from patients with leptospirosis and matching control group patients.

Retrospective data collection of underlying diseases: Retrospective data collection of underlying diseases from patients with leptospirosis and matching control group patients.

Retrospective data collection of duration of hospitalization: Retrospective data collection of duration of hospitalization from patients with leptospirosis and matching control group patients.

Study summary

Leptospirosis is a worldwide zoonotic diseases caused by pathogenic Leptospira spp. Human are accidental hosts, who acquired infections after exposition to animal urine, contaminated water or soil, infected tissue. Incidence of invasive leptospirosis disease causing acute kidney injury, acute respiratory distress syndrome (ARDS), myocarditis, hepatic dysfunction, hemorrhage and multi-organ failure, is globally increasing and there have been frequent outbreak situation throughout the world. Due to increasing outbreak situations and globally chances in species distributions, a worldwide surveillance in epidemiology and species distribution is urgently needed. The objective of the Leptospirosis Registry - LeptoScope is to overcome the lack knowledge on epidemiology, clinical course, prognostic factors and molecular characteristics for invasive leptospirosis disease.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Cultural, serological, molecular or histological evidence of invasive leptospirosis diseases * Clinical signs of disseminated leptospirosis disease without cultural, serological, molecular or histological evidence * Case controls: Matching procedures for controls: Particularly, case controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital). Exclusion Criteria: * Colonization or other non-invasive infection * Cultural, serological, molecular or histological evidence without dissemination

Primary outcome measure(s)

Incidence — up to 100 weeks
To describe the global incidence of invasive leptospirosis disease
Mortality — up to 100 weeks
To describe global mortality due to invasive leptospirosis disease

Trial sites (1)

Facility	City	Region	Status
University Hospital of Cologne	Cologne	North Rhine-Westphalia	Recruiting

More University of Cologne trials in Germany

Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy Recruiting

Vaccine-induced Immunity in Immunocompromised Patients Recruiting

Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse Active, not recruiting

Artificial Intelligence(AI) in the Emergency Department (ED) in Cologne Active, not recruiting

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04288674 on ClinicalTrials.gov ↗ ← All trials in Germany